The following editorial content was originally published here.
What if we could generate novel molecules to target any disease, overnight, ready for clinical trials? Imagine leveraging machine learning to accomplish with 50 people what the pharmaceutical industry can barely do with an army of 5,000. It’s a multibillion-dollar opportunity that can help billions.
The worldwide pharmaceutical market, one of the slowest monolithic industries to adapt, surpassed $1.1 trillion in 2016. In 2018, the top 10 pharmaceutical companies alone are projected to generate over $355 billion in revenue. At the same time, it currently costs more than $2.5 billion (sometimes up to $12 billion) and takes over 10 years to bring a new drug to market. Nine out of 10 drugs entering Phase I clinical trials will never reach patients. As the population ages, we don’t have time to rely on this slow, costly production rate. Some 12 percent of the world population will be 65 or older by 2030, and “diseases of aging” like Alzheimer’s will pose increasingly greater challenges to society. But a world of pharmaceutical abundance is already emerging. As artificial intelligence converges with massive datasets in everything from gene expression to blood tests, novel drug discovery is about to get more than 100 times cheaper, faster, and more intelligently targeted.
One of the hottest startups I know in this area is Insilico Medicine. Leveraging AI in its end-to-end drug pipeline, Insilico Medicine is extending healthy longevity through drug discovery and aging research. Their comprehensive drug discovery engine uses millions of samples and multiple data types to discover signatures of disease and identify the most promising targets for billions of molecules. These molecules either already exist or can be generated de novo with the desired set of parameters.
Insilico’s CEO Dr. Alex Zhavoronkov recently joined me on an Abundance Digital webinar to discuss the future of longevity research. Insilico announced the completion of a strategic round of funding led by WuXi AppTec’s Corporate Venture Fund, with participation from Pavilion Capital, Juvenescence, and my venture fund BOLD Capital Partners. What they’re doing is extraordinary — and it’s an excellent lens through which to view converging exponential technologies.
Case Study: Leveraging AI for Drug Discovery
You’ve likely heard of deep neural nets — multilayered networks of artificial neurons, able to ‘learn’ from massive amounts of data and essentially program themselves. Build upon deep neural nets, and you get generative adversarial networks (GANs), the revolutionary technology that underpins Insilico’s drug discovery pipeline.
What are GANs? By pitting two deep neural nets against each other (“adversarial”), GANs enable the imagination and creation of entirely new things (“generative”). Developed by Google Brain in 2014, GANs have been used to output almost photographically accurate pictures from textual descriptions (as seen below).
Source: Reed et al., 2016
Insilico and its researchers are the first in the world to use GANs to generate molecules. “The GAN technique is essentially an adversarial game between two deep neural networks,” as Alex explains. While one generates meaningful noise in response to input, the other evaluates the generator’s output. Both networks thereby learn to generate increasingly perfect output. In Insilico’s case, that output consists of perfected molecules. Generating novel molecular structures for diseases both with and without known targets, Insilico is pursuing drug discovery in aging, cancer, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, and many others.
Once rolled out, the implications would be profound. Alex’s ultimate goal is to develop a fully-automated Health as a Service (HaaS) / Longevity as a Service (LaaS) engine. Once plugged into the services of companies from Alibaba to Alphabet, such an engine would enable personalized solutions for online users, helping them prevent diseases and maintain optimal health. But what does this tangibly look like?
Insilico’s End-to-End Pipeline
First, Insilico leverages AI — in the form of GANs — to identify targets (as seen in the first stage of their pipeline below). To do this, Insilico uses gene expression data from both healthy tissue samples and those affected by disease. (Targets are the cellular or molecular structures involved in a given pathology that drugs are intended to act on.)
Source: Insilico Medicine via Medium
Within this first pipeline stage, Insilico can identify targets, reconstruct entire disease pathways and understand the regulatory mechanisms that result in aging-related diseases. This alone enables breakthroughs for healthcare and medical research. But it doesn’t stop there. After understanding the underlying mechanisms and causality involved in aging, Insilico uses GANs to ‘imagine’ novel molecular structures. With reinforcement learning, Insilico’s system lets you generate a molecule with any of up to 20 different properties to hit a specified target. This means that we can now identify targets like never before, and then generate custom molecules de novo such that they hit those specific targets. At scale, this would also involve designing drugs with minimized side effects, a pursuit already being worked on by Insilico scientist Polina Mamoshina in collaboration with Oxford University’s Computational Cardiovascular Team.
One of Insilico’s newest initiatives — to complete the trifecta, if you will — involves predicting the outcomes of clinical trials. While still in the early stages of development, accurate clinical trial predictors would enable researchers to identify ideal preclinical candidates. That’s a 10X improvement from today’s state of affairs.
Currently, over 90 percent of molecules discovered through traditional techniques and tested in mice end up failing in human clinical trials. Accurate clinical trial predictors would result in an unprecedented cutting of cost, time, and overhead in drug testing.
The 6 D’s of Drug Discovery
The digitization and dematerialization of drug discovery has already happened. Thanks to converging breakthroughs in machine learning, drug discovery and molecular biology, companies like Insilico can now do with 50 people what the pharmaceutical industry can barely do with an army of 5,000. As computing power improves, we’ll be able to bring novel therapies to market at lightning speeds, at much lower cost, and with no requirement for massive infrastructure and investments. These therapies will demonetize and democratize as a result. Add to this anticipated breakthroughs in quantum computing, and we’ll soon witness an explosion in the number of molecules that can be tested (with much higher accuracy).
Finally, AI enables us to produce sophisticated, multitarget drugs. “Currently, the pharma model, in general, is very simplistic. You have one target and one disease — but usually, a disease is not one target, it is many targets,” Alex has explained.
Inefficient, slow-to-innovate, and risk-averse industries will all be disrupted in the years ahead. Big Pharma is an area worth watching right now, no matter your industry. Converging technologies will soon enable extraordinary strides in longevity and disease prevention, with companies like Insilico leading the charge. Fueled by massive datasets, skyrocketing computational power, quantum computing, blockchain-enabled patient access, cognitive surplus capabilities and remarkable innovations in AI, the future of human health and longevity is truly worth getting excited about.
Rejuvenational biotechnology will be commercially available sooner than you think. When I asked Alex for his own projection, he set the timeline at “maybe 20 years — that’s a reasonable horizon for tangible rejuvenational biotechnology.” Alex’s prediction may even be conservative. My friend Ray Kurzweil often discusses the concept of “longevity escape velocity” — the point at which, for every year that you’re alive, science is able to extend your life for more than a year.
With a record-breaking prediction accuracy of 86 percent, Ray predicts “it’s likely just another 10 to 12 years before the general public will hit longevity escape velocity.” How might you use an extra 20 or more healthy years in your life? What impact would you be able to make?
Interested in exploring topics like this further? Join Peter Diamandis and Ray Kurzweil as they discuss Transforming Humanity in the 21st Century and Beyond, live-streamed from Ray’s Google office on September 14th. RSVP here.
Disclaimer: This guest post is in partnership with Abundance 360, and Futurism may get a small percentage of sales.
The post Artificial Intelligence Could Be The Key To Longevity [Affiliate] appeared first on Futurism.
Go here to read the rest:
Artificial Intelligence Could Be The Key To Longevity [Affiliate]
- Upcoming Space Hotel to Be “Like a Small Cruise Ship” - January 13th, 2019
- Just 41 Percent of Americans Support Advancing AI - January 13th, 2019
- Former Senator Wants Congress to Listen to UFO Reports - January 13th, 2019
- Google Brain Built a Translator so AI Can Explain Itself - January 13th, 2019
- Universal Internet Access Is at Least 30 Years Away, Say Experts - January 13th, 2019
- Astronomers May Have Just Spotted the Birth of a Black Hole - January 13th, 2019
- MIT Is Pouring Resources Into Commercializing Fusion Power - January 13th, 2019
- DARPA Wants to Build Conscious Robots Using Insect Brains - January 13th, 2019
- Surprise Announcement: SpaceX to Lay off 10 Percent of Workforce - January 13th, 2019
- One of the Closest Exoplanets to Earth Could Support Alien Life - January 13th, 2019
- A Black Hole Inhaled a Star. Then It Started to Shrink - January 13th, 2019
- Denmark Is Building Nine Gigantic Artificial Islands - January 13th, 2019
- Scientists Are Building a Quantum Computer That “Acts Like a Brain” - January 13th, 2019
- Scientists: Warming Oceans Will Lead to “Catastrophic” Future - January 13th, 2019
- New Technique Makes Electricity-Producing Bacteria More Useful Than Ever - January 13th, 2019
- Researchers Found the Blueprint for Plant Immune Systems - January 13th, 2019
- Russia’s Only Space Telescope Has Stopped Responding to Commands - January 13th, 2019
- Harvard Astronomer Predicts What First Alien Contact Will Be Like - January 13th, 2019
- A New Class of Drugs Could Make Safer Sleeping Pills - January 13th, 2019
- Researchers Repurposed CRISPR to Help Develop Better Antibiotics - January 13th, 2019
- Artificial intelligence - Wikipedia - January 3rd, 2019
- Online Artificial Intelligence Courses | Microsoft ... - January 3rd, 2019
- What is Artificial Intelligence (AI)? - Definition from ... - January 3rd, 2019
- Artificial Intelligence: The Robots Are Now Hiring - WSJ - January 3rd, 2019
- What is AI (artificial intelligence)? - Definition from ... - January 3rd, 2019
- Artificial Intelligence - Journal - Elsevier - January 3rd, 2019
- Benefits & Risks of Artificial Intelligence - Future of Life ... - January 3rd, 2019
- A.I. Artificial Intelligence - Wikipedia - January 3rd, 2019
- Artificial Intelligence: The Pros, Cons, and What to Really Fear - January 3rd, 2019
- A.I. Artificial Intelligence (2001) - IMDb - January 3rd, 2019
- Edible Coating Can Keep Food Fresh Longer and Cut Down on Waste - January 3rd, 2019
- Bill Gates: U.S. Leaders Must Embrace Nuclear Energy - January 3rd, 2019
- Spain Shuts Down 26 Unprofitable Coal Mines - January 3rd, 2019
- The Moons of Jupiter and Saturn Could Have Earth-Like Tidal Waves - January 3rd, 2019
- An Astronaut Accidentally Dialed 911 in Space - January 3rd, 2019
- Tiny Robots That Repair Pipes Could Eliminate Road Work - January 3rd, 2019
- Here’s NASA’s Newly-Released Image of Ultima Thule - January 3rd, 2019
- Astronomers Find First-of-Its-Kind Protostar With a “Warped” Disk - January 3rd, 2019
- NASA Scientist: Asteroid Deflection Mission Not Like “Armageddon” - January 3rd, 2019
- A Drill Built for Mars Will Probe Antarctic Bedrock - January 3rd, 2019
- Tesla’s Stock Plummets After It Cuts Price of All Models - January 3rd, 2019
- Nearly a Third of Norway’s 2018 New Car Sales Were Electric - January 3rd, 2019
- FCC Clears Google To Pursue “Minority Report”-Like Gesture System - January 3rd, 2019
- U.S. Plan to Restrict AI Exports Could Backfire - January 3rd, 2019
- A Wireless Neural Implant Might Jolt the Brain out of Seizures - January 3rd, 2019
- This Facial Recognition App Remembers Names so You Don’t Have To - January 3rd, 2019
- Hyundai Debuts a Walking Car With Four Legs - January 3rd, 2019
- Futuristic Hotel Suite Would Drive You Around While You Sleep - January 3rd, 2019
- China Just Landed a Rover on the Far Side of the Moon - January 3rd, 2019
- This Startup Wants to Send a Pregnant Woman to Space to Give Birth - January 3rd, 2019
- Elon Musk Thinks the First Mars Settler Could Be an AI - January 1st, 2019
- Leaked Documents Show How Facebook Controls Speech Across the Globe - January 1st, 2019
- Gov Shutdown Means 95 Percent of NASA Employees Aren’t At Work - January 1st, 2019
- Scientists to Test New Cancer Treatment on Human Patients in 2019 - January 1st, 2019
- Holograms Are Resurrecting Dead Musicians, Raising Legal Questions - January 1st, 2019
- New Theory: The Universe is a Bubble, Inflated by Dark Energy - January 1st, 2019
- Poll: Two Thirds of Americans Support Human Gene Editing to Cure Disease - January 1st, 2019
- Foreign Cyberattack Cripples Major U.S. Newspapers - January 1st, 2019
- Demand for Combustion Engine Cars May Have Peaked in 2018 - January 1st, 2019
- Scientist Who Gene Edited Babies Is Being Held By Mysterious Guards - January 1st, 2019
- Washington May Become the First State to Legalize Human Composting - January 1st, 2019
- NASA Clears “Dream Chaser” Space Cargo Plane For Full-Scale Production - January 1st, 2019
- Rerouting Nerves During Amputation May Reduce Phantom Limb Pain - January 1st, 2019
- Experts: Stop Adding Cancer-Causing Chemicals to our Meats - January 1st, 2019
- Google Wins Lawsuit Over Facial Recognition Technology - January 1st, 2019
- Tiny Robots That Repair Pipes Could Eliminate Road Work - January 1st, 2019
- Edible Coating Can Keep Food Fresh Longer and Cut Down on Waste - January 1st, 2019
- Bill Gates: U.S. Leaders Must Embrace Nuclear Energy - January 1st, 2019
- The EU Is Banning Almost All Coal Mining on Jan 1 - January 1st, 2019
- Stem cell - January 1st, 2019
- Stem Cell Therapy - Get Back To Your Life | Stem Cell Centers - January 1st, 2019
- Stem Cell Treatment | Arizona | Stem Cell Rejuvenation Center - January 1st, 2019
- Stem cell - Wikipedia - January 1st, 2019
- Stem Cell Therapy for Anti-Aging and Sexual Performance ... - January 1st, 2019
- NSI Stem Cell | What Is Stem Cell Therapy? - January 1st, 2019
- Stem Cell Therapy for Osteoarthritis - StemGenex - January 1st, 2019
- Stem Cell Research & Therapy | Home page - January 1st, 2019
- Stem Cells in Milwaukee, WI | Wisconsin Stem Cell Therapy - January 1st, 2019
- Stem Cell Therapy for Arthritis - January 1st, 2019
- National Stem Cell Centers | Stem Cell Therapy in New York ... - January 1st, 2019